Pulmonary hypertension biomarker
AssigneeNovartis AG
InventorsMarianna Rowlands, Clemence Anne Jeanne Marie Tessier, Paul Andrew Whittaker
Life of this patent
Estimating the term…
Abstract
Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.
Claims20
A method for treating a patient having pulmonary hypertension, comprising:
- a) assaying a biological sample selected from the group consisting of blood, serum and plasma obtained from the patient for the level of CCL21 expression and/or CCL21 protein;
- b) comparing the amount of CCL21 expression and/or of CCL21 protein to a baseline value that is indicative of the amount of CCL21 expression and/or of CCL21 protein in a subject that does not have pulmonary hypertension;
- and
- c) administering a therapeutically effective amount of a pulmonary hypertension antagonist if the patient has a statistically significant increased amount of CCL21 expression and/or of CCL21 protein compared to the baseline value, wherein the statistically significant increased amount is 1.5 fold or higher than the baseline value with a p-value of less than or equal to 0.05, as determined using a T-test.
A method for treating a patient having pulmonary hypertension, comprising:
- a) assaying a biological sample selected from the group consisting of blood, serum and plasma obtained from the patient for the level of CCL21 expression and/or CCL21 protein, wherein a nucleic acid sequence of CCL21 expression or a CCL21 protein or fragment thereof is assayed;
- b) comparing the amount of CCL21 expression and/or of CCL21 protein to a baseline value that is indicative of the amount of CCL21 expression and/or of CCL21 protein in a subject that does not have pulmonary hypertension;
- and
- c) administering a therapeutically effective amount of a pulmonary hypertension antagonist if the patient has a statistically significant increased amount of CCL21 expression and/or of CCL21 protein, wherein the statistically significant increased amount is 1.5 fold or higher than the baseline value with a p-value of less than or equal to 0.05, as determined using a T-test.
A method for treating a patient having pulmonary hypertension, comprising:
- a) assaying a biological sample selected from the group consisting of blood, serum and plasma obtained from the patient for the level of CCL21 expression and/or CCL21 protein;
- b) comparing the amount of CCL21 expression and/or of CCL21 protein to a baseline value that is indicative of the amount of CCL21 expression and/or of CCL21 protein in a subject that does not have pulmonary hypertension;
- and
- c) administering a therapeutically effective amount of a pulmonary hypertension antagonist if the patient has a statistically significant increased amount of CCL21 expression and/or of CCL21 protein, wherein the stastically significant increased amount is 1.5 fold or higher than the baseline value with a p-value of less than or equal to 0.05, as determined using a T-test, and
- wherein the pulmonary hypertension antagonist is selected from the group consisting of a calcium channel blocker, a phosphodiesterase (PDE) 5 inhibitor, a guanylate cyclase (sGC) stimulator, an endothelin receptor antagonist (ERA), and a prostacyclin agonist.
Dependencies are inferred from the claim text.